Q-omics provides the consensus-scored C6orf136 profile across patient tissues and cancer cell-line models. C6orf136 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, C6orf136 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, C6orf136 RNA expression shows 18,662 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, KIRC, and LSCC as cancer lineages where C6orf136 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C6orf136 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C6orf136 survival associations across molecular data types. C6orf136 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C6orf136 RNA expression–survival associations across cancer types. High C6orf136 expression shows unfavorable associations in BRCA and UCEC, but favorable associations in BLCA, KIRP, PAAD and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for C6orf136 RNA expression.
This table summarizes C6orf136 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C6orf136. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C6orf136 shows lower tumor expression in KIRC and COAD and higher tumor expression in STAD, LIHC, LUAD and LUSC. The KIRC box plot shows higher C6orf136 RNA expression in normal versus tumor tissue (log2 FC = −0.931, t-test p < 0.001).
This table shows molecular features associated with C6orf136 in patient tissues and cancer cell lines. In patient samples, C6orf136 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, C6orf136 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
